Early intervention with daratumumab may head off myeloma

Daratumumab monotherapy may be useful in patients with intermediate-risk or high-risk smouldering multiple myeloma (SMM) to delay their progression to MM. A phase 2 study of the monoclonal antibody in 123 patients from 47 sites worldwide...

Daratumumab monotherapy may be useful in patients with intermediate-risk or high-risk smouldering multiple myeloma (SMM) to delay their...

Bleeding disorders

Australian experience supports novel haemostatic agent efficacy in AHA

An Australian case series of six bleeds from four patients with acquired haemophilia A has provided further evidence to support the efficacy of recombinant porcine factor VIII (rpFVIII, Obizur) to treat bleeding in the condition. Dr Sally Campbell of the Australian...

An Australian case series of six bleeds from four patients with acquired haemophilia A has provided further evidence to...

Clotting disorders

PICC line thrombosis a challenge for adult oncology patients

Peripherally inserted central catheter (PICC) lines have again been shown to be associated with a higher rate of catheter-related thrombosis (CRT) than traditional central venous catheters (CVCs). A study of almost 5,000 central lines inserted in...

Peripherally inserted central catheter (PICC) lines have again been shown to be associated with a higher rate of...

Case study illustrates potential of venetoclax in MM subgroup

An interesting patient case demonstrating the safe and effective use of venetoclax for relapsed t(11;14) multiple myeloma in parallel with pembrolizumab for advanced non-small cell lung cancer (NSCLC) ‘strongly supports’ further development of venetoclax for this subset of multiple myeloma...

An interesting patient case demonstrating the safe and effective use of venetoclax for relapsed t(11;14) multiple myeloma in parallel with...